Isaacson argues that who patents, regulates, and profits from gene editing now matters as much as the science, because rewriting human heredity is no longer theoretical.

Spread the loveImagine looking in the mirror and seeing a younger version of yourself, not just cosmetically, but at a ...

Spread the loveImagine turning back the clock, not on your watch, but on your very own cells. It sounds like something ...

Key takeawaysCell reprogramming, which turns one cell type into another, is often inefficient because the genes needed for ...

The department of Biotechnology, Chandigarh College of Technology (CCT) CGC, Landran, organized a two-day national workshop ...

Despite an investment of 600 billion won, gene-editing research outcomes have failed to reach the industrialization stage due ...

ERS Genomics Limited ('ERS Genomics'), the CRISPR licensing company, today announced that it has signed a non-exclusive ...

UCLA researchers squeezed cells for milliseconds to briefly loosen their DNA, mapped where the DNA opened and aimed CRISPR ...

Researchers from Rice and Baylor College of Medicine have secured NIH funding to develop a novel, non-DNA-altering CRISPR ...

Called Cas12a2, the CRISPR system had some distinctive properties. Rather than editing cells’ DNA when prompted by a guide RNA, as CRISPR-Cas9 does, Cas12a2 indiscriminately shreds it, ultimately ...

A 2026 review describes CRISPR-Cas as a promising strategy for addressing drug-resistant Pseudomonas aeruginosa infections ...

A 2026 review summarizes advances in CRISPR-Cas9 precision, delivery and primary-cell engineering for genetic diseases and ...